Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 243

1.

Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.

Lorberbaum T, Sampson KJ, Chang JB, Iyer V, Woosley RL, Kass RS, Tatonetti NP.

J Am Coll Cardiol. 2016 Oct 18;68(16):1756-1764. doi: 10.1016/j.jacc.2016.07.761.

2.

Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

Schwartz PJ, Woosley RL.

J Am Coll Cardiol. 2016 Apr 5;67(13):1639-50. doi: 10.1016/j.jacc.2015.12.063. Review.

PMID:
27150690
3.

An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.

Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP.

Drug Saf. 2016 May;39(5):433-41. doi: 10.1007/s40264-016-0393-1.

4.

Farewell to our Good Friend and Outstanding Colleague David Flockhart (1952-2015).

Peck CC, Woosley RL.

Clin Pharmacol Ther. 2016 Feb;99(2):139-42. doi: 10.1002/cpt.327. No abstract available.

PMID:
26800329
5.

Medical decision support systems and therapeutics: The role of autopilots.

Woosley RL, Whyte J, Mohamadi A, Romero K.

Clin Pharmacol Ther. 2016 Feb;99(2):161-4. doi: 10.1002/cpt.259.

PMID:
26352903
6.

Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk.

Vicente J, Simlund J, Johannesen L, Sundh F, Florian J, Ugander M, Wagner GS, Woosley RL, Strauss DG.

J Electrocardiol. 2015 Jul-Aug;48(4):533-8. doi: 10.1016/j.jelectrocard.2015.03.011.

PMID:
25796102
7.

An interview with Raymond L. Woosley.

Woosley RL.

Trends Pharmacol Sci. 2014 Jul;35(7):305-7. doi: 10.1016/j.tips.2014.05.002. No abstract available.

PMID:
24913995
8.

Assessing cardiovascular drug safety for clinical decision-making.

Woosley RL, Romero K.

Nat Rev Cardiol. 2013 Jun;10(6):330-7. doi: 10.1038/nrcardio.2013.57. Review.

PMID:
23591268
9.

Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics.

Postema PG, Neville J, de Jong JS, Romero K, Wilde AA, Woosley RL.

Europace. 2013 Jul;15(7):1042-9. doi: 10.1093/europace/eut018.

10.

It is important research, but why is it necessary?

Woosley RL.

Clin Pharmacol Ther. 2013 Apr;93(4):297-9. doi: 10.1038/clpt.2013.15.

PMID:
23511783
11.

Regulatory and reimbursement innovation.

Lindor RA, Allocco SJ, Cheatham L, Cortese DA, Hall RF, Mangold WJ Jr, Pizziconi V, Poste G, Quinn B, Roth M, Saks MJ, Wassman ER, Woosley RL, Marchant GE.

Sci Transl Med. 2013 Mar 13;5(176):176cm3. doi: 10.1126/scitranslmed.3005437.

PMID:
23486776
12.

One hundred years of drug regulation: where do we go from here?

Woosley RL.

Annu Rev Pharmacol Toxicol. 2013;53:255-73. doi: 10.1146/annurev-pharmtox-011112-140159. Review.

PMID:
23072378
13.

Is it possible for FDA regulatory scientists and industry scientists to work together?

Woosley RL.

Clin Pharmacol Ther. 2012 Mar;91(3):390-2. doi: 10.1038/clpt.2011.304.

PMID:
22343817
14.

Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs.

Hines LE, Ceron-Cabrera D, Romero K, Anthony M, Woosley RL, Armstrong EP, Malone DC.

Clin Ther. 2011 Jan;33(1):36-45. doi: 10.1016/j.clinthera.2011.01.021.

PMID:
21397772
15.

Community pharmacy and pharmacist staff call center: assessment of medication safety and effectiveness.

Higgins L, Brown M, Murphy JE, Malone DC, Armstrong EP, Woosley RL.

J Am Pharm Assoc (2003). 2011 Jan-Feb;51(1):82-9. doi: 10.1331/JAPhA.2011.09108.

PMID:
21247830
16.

Research at the interface of industry, academia and regulatory science.

Mattes WB, Walker EG, Abadie E, Sistare FD, Vonderscher J, Woodcock J, Woosley RL.

Nat Biotechnol. 2010 May;28(5):432-3. doi: 10.1038/nbt0510-432. No abstract available.

PMID:
20458309
17.

The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.

Woosley RL, Myers RT, Goodsaid F.

Clin Pharmacol Ther. 2010 May;87(5):530-3. doi: 10.1038/clpt.2010.27. Review.

PMID:
20407457
18.

The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases.

Romero K, de Mars M, Frank D, Anthony M, Neville J, Kirby L, Smith K, Woosley RL.

Clin Pharmacol Ther. 2009 Oct;86(4):365-7. doi: 10.1038/clpt.2009.165.

PMID:
19763117
19.

Time to replace Bazett's QT-correction.

Woosley RL, Romero K.

Pacing Clin Electrophysiol. 2009 Nov;32(11):1379-80. doi: 10.1111/j.1540-8159.2009.02513.x. No abstract available.

PMID:
19712074
20.

Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium.

Anthony M, Romero K, Malone DC, Hines LE, Higgins L, Woosley RL.

Clin Pharmacol Ther. 2009 Oct;86(4):425-9. doi: 10.1038/clpt.2009.95.

PMID:
19587643
Items per page

Supplemental Content

Loading ...
Support Center